bioRxivImmunologyPreprint
Synergistic Hypoxia and Apoptosis Conditioning Unleashes Superior Mesenchymal Stem Cells Efficacy in Acute Graft-versus-Host-Disease
M. Mendiratta, M. Mendiratta, S. K. Ganguly, S. Rai, R. Gupta, L. Kumar, S. Bakhshi, V. Dadhwal, D. Pushpam, P. S. Malik, R. Pramanik, M. Aggarwal, A. K. Gupta, R. Dhawan, T. Seth, M. Mahapatra, B. Nayak, T. D. Singh, S. K. Singla, M. Singh, C. P. Prasad, H. Prakash, S. Mohanty, R. K. Sahoo
Abstract
Mesenchymal stem cells (MSCs) have emerged as promising candidates for immune modulation in various diseases that are associated with dysregulated immune responses like Graft-versus-Host-Disease (GVHD). MSCs are pleiotropic and the fate of MSCs following administration is a major determinant of their therapeutic efficacy. In this context, we here demonstrate that hypoxia preconditioned apoptotic MSCs [bone marrow (BM), Whartons Jelly (WJ)] bear more immune programming ability in a cellular model of acute Graft-versus-Host-Disease (aGVHD). To this purpose, we programmed MSCs by exposing them to hypoxia and inducing apoptosis both sequentially as well as simultaneously. Our findings demonstrated that WJ MSCs that were conditioned with indicated approaches simultaneously induced the differentiation of CD4+T-cell towards Tregs, enhanced Th2 effector, and concomitantly mitigated Th1 and Th17, with polarization of M1 effector macrophages towards their M2 phenotype, and more interestingly enhanced efferocytosis by macrophages indicated Th2 programming ability of MSCs programmed by conjunctional approaches Overall, our study highlights the potential of WJ-MSCs conditioned with hypoxia and apoptosis concurrently, as a promising therapeutic strategy for aGVHD and underscores the importance of considering MSC apoptosis in optimizing MSCs-based cellular therapy protocols for enhanced therapeutic efficacy in aGvHD. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=123 HEIGHT=200 SRC="FIGDIR/small/588248v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@92c102org.highwire.dtl.DTLVardef@bd895forg.highwire.dtl.DTLVardef@185e041org.highwire.dtl.DTLVardef@45ef0f_HPS_FORMAT_FIGEXP M_FIG C_FIG
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- research focus: development & morphogenesis
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hypoxia-Mediated Molecular Interactions of Tissue-Specific Mesenchymal Stem Cells Drive Metabolic Reprogramming and Immunomodulation in Acute Graft-versus-Host Disease
Mohini Mendiratta, Meenakshi Mendiratta, … Ranjit Kumar Sahoo·bioRxiv·Jan 6, 2025
- Dual Preconditioned Mesenchymal Stem Cells-Derived Culture Conditioned Media Augment Immunomodulation and Drive Metabolic Reprogramming in Acute Graft-versus-Host Disease
Mohini Mendiratta, Meenakshi Mendiratta, … Ranjit Kumar Sahoo·bioRxiv·Nov 2, 2025
- Dose-Response Immunomodulatory Effects of Mesenchymal Stem Cells-Derived Culture-Conditioned Media in Acute Graft-versus-Host-Disease
Mohini Mendiratta, Meenakshi Mendiratta, … Ranjit Kumar Sahoo·Regenerative TherapyPeer-reviewed·Oct 9, 2025
- Independent human mesenchymal stromal cell-derived extracellular vesicle preparations differentially affect symptoms in an advanced murine Graft-versus-Host-Disease model
R. J. Madel, V. Börger, … B. Giebel·bioRxiv·Dec 21, 2020
- Secondary lymphoid organ endothelial cells prime alloreactive CD4+ T cells to trigger acute graft-versus-host disease
Haroon Shaikh, Pia Wittmann, … Andreas Beilhack·bioRxiv·Oct 7, 2025
- CD40 provides immune privilege to the bone marrow hematopoietic niche
B. Bassani, A. Gulino, … S. Sangaletti·bioRxiv·Aug 10, 2020